InvestorsHub Logo
Followers 5
Posts 563
Boards Moderated 0
Alias Born 08/19/2020

Re: None

Thursday, 04/21/2022 3:46:12 PM

Thursday, April 21, 2022 3:46:12 PM

Post# of 2719
$OPGN $NVS Sandoz collaboration extended to Jan 2025.

Sandoz (Novartis sub) CEO Richard Saynor: "As the world’s leading provider of generic antibiotics, our goal at Sandoz is to play a key role in overcoming this growing threat (AMR). This collaboration (with OpGen’s subsidiary Ares Genetics) is a key step towards that goal, allowing us to take the fight directly to AMR by using cutting-edge big data and AI approaches combined with traditional data sets."

OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
https://finance.yahoo.com/news/opgen-subsidiary-ares-genetics-provides-113000156.html

Novartis (NVS) Market cap: US$203.15 Billion as of April 2022.

Why would one of world's largest pharmaceutical firms form a key partnership with little OPGEN unless OPGEN had what Novartis needed?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OPGN News